Across TCGA pan-cancer cohorts, SFMBT2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SFMBT2 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SFMBT2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SFMBT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.
OV, UCEC, and HNSC are the cancer types where SFMBT2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.